It is a synthetic peptide modelled on residues 176191 of the C-terminal end of human growth hormone, modified by adding a tyrosine residue to the N-terminus to improve stability
The highest monotherapy dose studied is 4.5 mg per week (Lancet 2021 Phase 2)
Based on cross-trial data, CagriSema and tirzepatide produce nearly identical weight loss results, approximately 22 to 23% in non-diabetic populations with obesity
Because peptide therapy can be tailored to each individuals unique needs, it is an increasingly popular choice for those seeking alternative or complementary treatment options
Thus, genetically determined increased TLR2 level (rs1816702), MD-2 level (rs11465996), TNFRSF1A (TNFR1) expression (rs4149570) and genetically determined decreased IL-1 (rs3804099), IL-6 (rs3804099) and IFN- (rs2430561) levels were associated with beneficial response among patients with CD